Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory
Outlook Therapeutics got permission from the government to sell a new eye medicine for people with vision loss from aging. This is a big win because the company spent years testing it, and now doctors can use it to help patients see better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.